Effects of intestinal microbiota on the bioavailability of geniposide in rats

J Agric Food Chem. 2014 Oct 8;62(40):9632-6. doi: 10.1021/jf502557f. Epub 2014 Sep 26.


This study investigated the effects of intestinal microbiota on the metabolism of geniposide by using a rat model treated with a mixture of antibiotics. The plasma concentration of geniposide was determined after oral administration in control and antibiotics-treated rats by using liquid chromatography-tandem mass spectrometry. The maximum plasma concentrations (Cmax) of geniposide in control and antibiotics-treated rats were 0.91 ± 0.26 and 1.01 ± 0.04 μg/mL, respectively, and the area under the curve (AUC) values were 7.34 ± 3.32 and 11.9 ± 2.1 μg·h/mL (p < 0.05), respectively. The levels of geniposide in rat feces were 0.64 and 15.6 mg, respectively, in the control and antibiotics-treated groups. Thus, the systemic exposure of geniposide was greater in the antibiotics-treated rats. This may be due to the antibiotic-induced suppression of the metabolic activities of the intestinal microbiota. These results suggest that the gut microbiota may have an impact on the bioavailability of geniposide.

Keywords: bioavailability; geniposide; intestinal microbiota; metabolism.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Biological Availability
  • Intestines / drug effects*
  • Intestines / microbiology*
  • Iridoids / administration & dosage
  • Iridoids / pharmacokinetics*
  • Male
  • Microbiota* / drug effects
  • Rats, Sprague-Dawley


  • Iridoids
  • geniposide